FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:460-461 August 17, 1995 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Winawer, S. J. Related Article by Toribara, N. W. PubMed Citation

To the Editor: Toribara and Sleisenger (March 30 issue)¹ reviewed screening for colorectal cancer. Since 1992 prospective and case–control studies, such as that by Wahrendörf et al.,² have shown a decreased mortality rate for colorectal cancer with the use of the Hemoccult II fecal occult-blood test. There is now strong evidence that it is possible to decrease mortality by screening with Hemoccult II persons older than 50 years of age. The evidence is as strong as that for mammography for breast-cancer screening, and stronger than that for Pap smears for cervical-cancer screening, for which there are no prospective studies. Since . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Schoneberger, A. A., Schmidt, K., Cequier, A., Sabate, M., Esplugas, E., Neumann, F.-J., Walter, H., Schomig, A. (1996). Antiplatelet and Anticoagulant Therapy after Coronary-Artery Stenting. NEJM 335: 1160-1161 [Full Text]